Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years
- 15 December 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (24), 6475-6482
- https://doi.org/10.1158/1078-0432.CCR-20-3134
Abstract
Purpose: Relapsed acute myeloid leukemia (AML) post allogeneic hematopoietic cell transplantation (allo-HCT) has a dismal prognosis. Experimental Design: To assess prognosis of patients with recurrent A MI. post alto-HCT over time, we analyzed European Society for Blood and Marrow Transplantation registry data of 8,162 adult patients with AML who relapsed between 2000 and 2018 after allo-HCT performed in first complete remission from matched sibling, unrelated, or haploidentical donors. Results: The 2-year overall survival (OS) rate from relapse was 17%. For 3,630 patients, 50 years of age, the year of relapse had no influence on OS (16% for 2000-2004 and 14% for 2015-2018; P = 0.56). Regarding treatment, encouraging results were observed after second allo-HCT, which was performed within 2 years after relapse in 17% of the entire cohort, resulting in a 2-year OS of 30.7%. Conclusions: Outcome after posuransplant relapse among younger patients has improved significantly in recent years, likely reflecting, among other factors, the efficacy of posttransplant salvage including second allo-HCT.Other Versions
Funding Information
- no fuding (NA)
This publication has 30 references indexed in Scilit:
- Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor ChangeJournal of Clinical Oncology, 2013
- NIH-defined graft-versus-host disease after reduced intensity or myeloablative conditioning in patients with acute myeloid leukemiaLeukemia, 2011
- Relapse after Allogeneic Hematopoietic Cell TherapyTransplantation and Cellular Therapy, 2010
- Defining the Intensity of Conditioning Regimens: Working DefinitionsTransplantation and Cellular Therapy, 2009
- Management of relapse after allo-SCT for AML and the role of second transplantationBone Marrow Transplantation, 2009
- Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working PartyJournal of Clinical Oncology, 2007
- Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantationLeukemia, 2007
- Treatment of Relapsed Acute Leukemia after Allogeneic Transplantation: A Single Center ExperienceTransplantation and Cellular Therapy, 2007
- Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplantBone Marrow Transplantation, 2004
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974